NLS Pharmaceutics AG Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019	2018
Market Capitalization	8	21	23	13	-	-	Upgrade
Market Cap Growth	57.08%	-8.29%	71.28%	-	-	-	Upgrade
Enterprise Value	9	22	14	8	2	1	Upgrade
PE Ratio	-	-1.73	-1.39	-1.12	-	-	Upgrade
PB Ratio	-2.38	-2.38	6.99	24.70	-	-	Upgrade
P/FCF Ratio	-2.17	-2.17	-1.65	-0.89	-	-	Upgrade
P/OCF Ratio	-2.17	-2.17	-1.65	-0.90	-	-	Upgrade
EV/EBITDA Ratio	-1.81	-1.81	-0.85	-0.67	-0.76	-0.13	Upgrade
EV/EBIT Ratio	-1.81	-1.81	-0.85	-0.67	-0.76	-0.13	Upgrade
EV/FCF Ratio	-2.25	-2.25	-1.01	-0.53	-2.73	-3.27	Upgrade
Debt / Equity Ratio	-0.18	-0.18	-	-	-0.23	-0.14	Upgrade
Debt / EBITDA Ratio	-0.14	-0.14	-	-	-0.79	-0.18	Upgrade
Debt / FCF Ratio	-0.17	-0.17	-	-	-2.86	-4.43	Upgrade
Quick Ratio	0.11	0.11	2.66	2.26	0.01	0.05	Upgrade
Current Ratio	0.23	0.23	2.75	2.38	0.03	0.10	Upgrade
Interest Coverage	-82.86	-82.86	-162.54	-174.33	-11.24	-5.65	Upgrade
Return on Equity (ROE)	438.40%	438.40%	-862.90%	283.00%	37.80%	72.70%	Upgrade
Return on Assets (ROA)	-218.90%	-218.90%	-219.30%	-342.50%	-299.90%	-1293.80%	Upgrade
Return on Capital (ROIC)	163.99%	163.99%	-471.90%	-2186.74%	33.33%	78.76%	Upgrade
Earnings Yield	-144.81%	-57.84%	-71.90%	-89.18%	-	-	Upgrade
FCF Yield	-115.21%	-46.02%	-60.49%	-111.79%	-	-	Upgrade
Buyback Yield / Dilution	-220.76%	-93.96%	-65.38%	-71.00%	-1.75%	-9.62%	Upgrade
Total Shareholder Return	-220.76%	-93.96%	-65.38%	-71.00%	-1.75%	-9.62%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).